Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.

Codiak Biosciences, a US-based exosome therapeutics developer backed by life science real estate investment trust Alexandria Real Estate Equities, has withdrawn its plans for an $86.3m initial public offering. Douglas Williams, chief executive of Codiak, cited unfavourable market conditions for the company’s decision. Codiak had filed for an IPO in April 2019 and was hoping…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.